Enliven Therapeutics Gains FDA Approval for ENABLE-2 Trial of Relcobatinib in CML Patients

Enliven Therapeutics Gains FDA Approval for ENABLE-2 Trial of Relcobatinib

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company based in Burlingame, California, has announced important news regarding its experimental drug, relcobatinib (ELVN-001). In a significant step forward, the company has received alignment from the U.S. Food and Drug Administration (FDA) on the final design of its ENABLE-2 clinical trial. This trial is pivotal, being Phase 3 of relcobatinib targeted at patients suffering from previously treated chronic myeloid leukemia (CML).

Relcobatinib stands out as a potent, highly selective small molecule kinase inhibitor designed to specifically target the BCR-ABL1 gene fusion, which is known to drive the oncogenesis of CML. The general name for relcobatinib has been officially adopted by the United States Adopted Names (USAN) Council, marking its importance in treating this disease.

Dr. Helen Collins, Chief Medical Officer at Enliven, expressed optimism regarding the development, stating, "We are pleased to have reached alignment with the FDA on the design of the ENABLE-2 pivotal Phase 3 trial, providing a clear path to initiate the trial before year-end." She emphasized that this trial is structured to directly compare relcobatinib with second-generation tyrosine kinase inhibitors (TKIs) and assess its potential as a best-in-class ATP-competitive inhibitor for CML patients.

ENABLE-2 Phase 3 Trial Design

The ENABLE-2 trial aims to enroll roughly 450 adult participants who have previously undergone one or more treatments with TKI therapies. This randomized trial will compare two groups: one receiving relcobatinib at a dosage of 80 mg once daily and the other receiving a second-generation TKI selected by investigators, which may include dasatinib, nilotinib, or bosutinib.

The primary endpoint of the trial is achieving a major molecular response (MMR) at the 24-week mark. A key secondary endpoint involves measuring MMR at 96 weeks. To ascertain the efficacy of relcobatinib, researchers will look for a minimum improvement of ten percentage points in MMR compared to the control group—an enhancement that could represent a clinically significant advancement over the second-generation TKIs currently available.

Given the clarity of the trial's objectives and structure, Enliven is positioned to commence the ENABLE-2 trial before the end of 2026, and they are enthusiastic about the positive feedback received from physicians and the broader CML community.

About Enliven Therapeutics

Enliven Therapeutics focuses on the development of small molecule therapeutics aimed not only at extending life but also improving the quality of life for patients. The company addresses both existing and emerging unmet needs through a precision medicine strategy designed to enhance survival and overall well-being. Enliven’s research methodology integrates deep understanding of clinically validated biological targets with innovative chemistry to create potentially groundbreaking therapies.

For more information, please visit their website at www.enliventherapeutics.com and follow them on social media platforms like LinkedIn and X for updates.

Conclusion

The alignment of the ENABLE-2 trial with FDA standards represents a critical milestone for Enliven Therapeutics and those affected by chronic myeloid leukemia. As investigational medications like relcobatinib progress through clinical trials, they bring hope for better treatment options and improved outcomes for patients in this challenging arena of oncology.